Veterans Marijuana Policy Faces Congressional Scrutiny as Lawmakers Push for Reform
Expressing “deep concern,” a group of bipartisan congressional lawmakers is raising questions about the U.S. Department of Veterans Affairs (VA) marijuana directive. This directive, which continues to prohibit VA doctors from providing medical cannabis recommendations to veterans residing in states where its use is legal, has caught the attention of legislators on both sides of the aisle.
In a letter addressed to VA Secretary Denis McDonough, key members of the Congressional Cannabis Caucus have come forward to voice their reservations. Reps. Barbara Lee (D-CA), Earl Blumenauer (D-OR), and Dave Joyce (R-OH), the co-chairs of the caucus, have highlighted their worries regarding the VA’s stance on medical cannabis. They argue that the VA is overlooking a vital treatment option for veterans with conditions such as post-traumatic stress disorder (PTSD) and chronic pain.
The lawmakers underscore the urgency of this matter, particularly concerning VA’s recent clinical guidance on PTSD. This guidance strongly advises against the utilization of medical cannabis as a potential treatment avenue. Such a decision, they assert, perpetuates a “harmful policy” that inhibits veterans from accessing potentially effective medical solutions.
The legislators point out their previous efforts to effect change in this realm. They remind Secretary McDonough of their successful push to amend a House appropriations bill. This amendment aimed to grant VA doctors the ability to recommend medical cannabis to veterans in need. A similar reform also secured passage through the Senate Appropriations Committee as part of its appropriations legislation.
According to the lawmakers, providing VA healthcare providers the discretion to consider medical cannabis could significantly enhance the well-being of veterans. They believe that this approach would prevent veterans from having to self-medicate or seek alternative care options outside the VA system. Furthermore, they emphasize that this reform would not expose providers to potential federal prosecution.
Citing the experiences of veterans who already use cannabis for medical purposes, the lawmakers contend that many veterans report improved quality of life and decreased reliance on prescription drugs, including opioids. They argue that it’s time for the VA to align with prevailing trends and expert opinions.
While the VA had previously added language encouraging discussions about veterans’ marijuana use in its 2017 directive, the most recent update continues to raise concerns. VA providers are allowed to discuss marijuana use with veterans and record this information in their health records. However, calls for more comprehensive reform persist from various quarters, including veterans groups, advocates, and lawmakers.
Despite the ongoing debate and pressure for change, the VA remains resistant to the idea of its doctors issuing medical cannabis recommendations or initiating clinical trials to examine the effectiveness of marijuana in treating health conditions that often afflict veterans.
In summary, the issue of veterans’ access to medical cannabis remains a point of contention on Capitol Hill. Bipartisan lawmakers are uniting to challenge the VA’s existing policies, urging the department to reconsider its stance and align with the evolving landscape of medical cannabis legalization and research.
